LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (Nasdaq:HYTM), the healthcare services management company that licenses the PROMETA™ treatment protocols designed to treat alcohol, methamphetamine and cocaine dependence, today announced that it is scheduled to report financial results for its third quarter ended September 30, 2006 on Thursday, November 9, 2006, after the market closes.
